Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAMOND trial of patiromer to maintain RAAS inhibitor therapy in heart failure patients with hyperkalemia
MOH_2020-01-01_008506Phase 3Not yet recruiting
- Sponsor
- Relypsa, Inc.
- Start
- Oct 2019
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hyperkalemia and heart failure with reduced ejection fraction (HFrEF) comparing Patiromer continuation with Placebo after patiromer withdrawal (2 arms). Primary endpoint: Composite of cardiovascular death and cardiovascular hospitalization. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
patiromer
03
Conditions
hyperkalemiaheart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on MOH_2020-01-01_008506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-01-01_008506.